Atrial fibrillation after brain hemorrhage

Patients with atrial fibrillation (a heart rhythm disorder) often take anticoagulants to prevent strokes caused by blood clots. However, when a person has already survived a cerebral hemorrhage (a severe form of stroke caused by bleeding in the brain), restarting these medications raises a delicate question: do the benefits outweigh the risks?

A large European study, called PRESTIGE-AF , attempted to answer this question. It followed 319 patients in 6 European countries, all with atrial fibrillation and who had survived a cerebral hemorrhage. These patients were randomized into two groups: one received a direct oral anticoagulant (DOAC) , the other did not.

• Patients treated with a DOAC had significantly fewer ischemic strokes (caused by clots) than those who did not take one.
• However , these same patients experienced many more recurrences of cerebral hemorrhage , a serious side effect.
• In simple terms: the drug protects against one type of stroke but increases the risk of another .
• Serious adverse events were generally slightly less frequent in the group receiving anticoagulants.

In individuals with a history of cerebral hemorrhage, DOACs can be highly effective in preventing strokes related to atrial fibrillation (embolisms), but they significantly increase the risk of recurrent cerebral hemorrhage. Researchers emphasize that further studies and potentially new approaches (pharmacological or mechanical) will be needed to protect these high-risk patients without exposing them to new dangers.